73 research outputs found
Successful Use of Extracorporeal Life Support after Double Traumatic Tracheobronchial Injury in a Patient with Severe Acute Asthma
We report the case of an asthmatic patient with blunt trachea and left main bronchus injuries who developed acute severe asthma after surgical repair. Despite medical treatment and ventilatory support, asthma persisted with high airway pressures and severe respiratory acidosis. We proposed venovenous extracorporeal life support for CO2 removal which allowed arterial blood gas normalization and airway pressures decrease. Extracorporeal life support was removed on day five after medical treatment of acute severe asthma. So we report the successful use of extracorporeal life support for operated double blunt tracheobronchial injury with acute severe asthma
Bradykinin and adenosine receptors mediate desflurane induced postconditioning in human myocardium: role of reactive oxygen species
BACKGROUND:
Desflurane during early reperfusion has been shown to postcondition human myocardium, in vitro. We investigated the role of adenosine and bradykinin receptors, and generation of radical oxygen species in desflurane-induced postconditioning in human myocardium.
METHODS:
We recorded isometric contraction of human right atrial trabeculae hanged in an oxygenated Tyrode's solution (34 degrees Celsius, stimulation frequency 1 Hz). After a 30-min hypoxic period, desflurane 6% was administered during the first 5 min of reoxygenation. Desflurane was administered alone or with pretreatment of N-mercaptopropionylglycine, a reactive oxygen species scavenger, 8-(p-Sulfophenyl)theophylline, an adenosine receptor antagonist, HOE140, a selective B2 bradykinin receptor antagonist. In separate groups, adenosine and bradykinin were administered during the first minutes of reoxygenation alone or in presence of N-mercaptopropionylglycine. The force of contraction of trabeculae was recorded continuously. Developed force at the end of a 60-min reoxygenation period was compared (mean +/- standard deviation) between the groups by a variance analysis and post hoc test.
RESULTS:
Desflurane 6% (84 +/- 6% of baseline) enhanced the recovery of force after 60-min of reoxygenation as compared to control group (51 +/- 8% of baseline, P < 0.0001). N-mercaptopropionylglycine (54 +/- 3% of baseline), 8-(p-Sulfophenyl)theophylline (62 +/- 9% of baseline), HOE140 (58 +/- 6% of baseline) abolished desflurane-induced postconditioning. Adenosine (80 +/- 9% of baseline) and bradykinin (83 +/- 4% of baseline) induced postconditioning (P < 0.0001 vs control), N-mercaptopropionylglycine abolished the beneficial effects of adenosine and bradykinin (54 +/- 8 and 58 +/- 5% of baseline, respectively).
CONCLUSIONS:
In vitro, desflurane-induced postconditioning depends on reactive oxygen species production, activation of adenosine and bradykinin B2 receptors. And, the cardioprotective effect of adenosine and bradykinin administered at the beginning of reoxygenation, was mediated, at least in part, through ROS production
Perioperative hemodynamic optimization using the photoplethysmography in colorectal surgery (the PANEX3 trial): study protocol for a randomized controlled trial
Mortalité du traumatisé grave à trente jours (recherche de facteurs prédictifs au cours de la prise en charge des quarante-huit premiÚres heures)
CAEN-BU MĂ©decine pharmacie (141182102) / SudocPARIS-BIUM (751062103) / SudocSudocFranceF
Le préconditionnement et le postconditionnement induits par les médicaments de l'anesthésie sur le myocarde humain in vitro et in vivo
CAEN-BU MĂ©decine pharmacie (141182102) / SudocSudocFranceF
Audit régional sur la formation médicale continue des anesthésistes réanimateurs de Basse-Normandie
CAEN-BU MĂ©decine pharmacie (141182102) / SudocSudocFranceF
ArrĂȘt cardiaque intra-hospitalier au CHU de Caen en 2010 (Ă©valuation et perspectives)
CAEN-BU MĂ©decine pharmacie (141182102) / SudocSudocFranceF
Incidence et prise en charge de la difficulté de ventilation à l'induction de l'anesthésie au CHU de Caen
CAEN-BU MĂ©decine pharmacie (141182102) / SudocPARIS-BIUM (751062103) / SudocSudocFranceF
Morbidités et mortalité de l'hémorragie aiguë grave avec état de choc
CAEN-BU MĂ©decine pharmacie (141182102) / SudocPARIS-BIUM (751062103) / SudocSudocFranceF
- âŠ